A
AtaiBeckley Inc. (ATAI)
NGM – Real vaqt narxi. Valyuta: USD
4.15
+0.11 (2.72%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.17
+0.02 (0.43%)
Bozor oldidan: May 13, 2026, 4:14 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
4.15
+0.11 (2.72%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.17
+0.02 (0.43%)
Bozor oldidan: May 13, 2026, 4:14 AM EDT
AtaiBeckley Inc., klinik tadqiqot bosqichidagi biofarmatsevtika kompaniyasi, Amerika Qo'shma Shtatlari, Germaniya va Kanadada ruhiy salomatlikni davolashni tadqiq qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya BPL-003 ni ishlab chiqadi, bu mebufoteninning benzoat tuz shaklining burun spreyi shakli bo'lib, u davolashga chidamli depressiya (TRD) va alkogolga bog'liqlikni davolash uchun 2a va 2b klinik tadqiqotlar bosqichida; RL-007, og'iz orqali qabul qilinadigan, kognitiv buzilishlarni davolashda foydalaniladigan neyromodulyator, shizofreniya bilan bog'liq kognitiv buzilishlar uchun 2b bosqichida; va ELE-101, katta depressiv buzilishlarni davolash uchun serotoninli psixodelik. Shuningdek, kompaniya TRD ni davolash uchun 2-bosqichli klinik tadqiqotda bo'lgan N,N-Dimetiltriptaminning og'iz orqali translyozal plyonkasi shakli bo'lgan VLS-01 ni; ijtimoiy xavotirni davolash uchun 2-bosqichli klinik tadqiqotda bo'lgan R-3,4-metilendioksi-metamfetaminning og'iz orqali qabul qilinadigan shakli bo'lgan EMP-01 ni; va TRD uchun galüsinogen bo'lmagan 5-HT2A retseptorlari agonistlari bo'lgan EGX-A va EGX-B ni ishlab chiqmoqda. Bundan tashqari, kompaniya psilosibin terapiyasi uchun COMP360 ni; va xavotir, depressiya va turli nevrologik kasalliklarni davolash uchun GRX-917 ni taklif etadi. Kompaniya ilgari Atai Beckley N.V. nomi bilan tanilgan va 2025 yil dekabr oyida AtaiBeckley Inc. nomini o'zgartirgan. AtaiBeckley Inc. 2018 yilda tashkil etilgan va Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Gerd G. Kochendoerfer Ph.D. | Chief Operating Officer |
| Dr. Glenn Short Ph.D. | Chief Scientific Officer |
| Dr. Jason Awe Ph.D. | Vice President of Investor Relations |
| Dr. Kevin Craig M.D. | Chief Medical Officer |
| Dr. Robert Conley M.D. | Chief Research & Development Officer |
| Dr. Srinivas G. Rao M.D., Ph.D. | Co-Founder, CEO & Executive Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 8-K | ef20072731_8k.htm |
| 2026-04-22 | DEF 14A | ny20067706x1_def14a.htm |
| 2026-03-09 | S-3ASR | ny20064952x1_s3asr.htm |
| 2026-03-06 | 8-K | ef20066741_8k.htm |
| 2026-03-06 | 10-K | atai-20251231.htm |
| 2026-02-26 | 8-K | ef20066456_8k.htm |
| 2026-02-19 | 8-K | ef20066047_8k.htm |
| 2025-12-31 | POSASR | ef20061810_posasr.htm |
| 2025-12-31 | 15-12G | ef20061613_15-12g.htm |
| 2025-12-05 | 8-K | ny20060616x1_8k.htm |
| Mr. Christian Angermayer | Co-Founder & Chairman of the Board |
| Mr. Michael Eric Faerm | Chief Financial Officer |
| Mr. Ryan Barrett J.D. | Chief Legal & Business Officer |
| Ms. Anne Johnson CPA | Chief Accounting Officer |